196 related articles for article (PubMed ID: 20633303)
1. A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.
Leelahavarong P; Chaikledkaew U; Hongeng S; Kasemsup V; Lubell Y; Teerawattananon Y
BMC Health Serv Res; 2010 Jul; 10():209. PubMed ID: 20633303
[TBL] [Abstract][Full Text] [Related]
2. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.
Sruamsiri R; Chaiyakunapruk N; Pakakasama S; Sirireung S; Sripaiboonkij N; Bunworasate U; Hongeng S
BMC Health Serv Res; 2013 Feb; 13():45. PubMed ID: 23379888
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
[TBL] [Abstract][Full Text] [Related]
4. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis.
Aungsumart S; Apiwattanakul M
PLoS One; 2020; 15(2):e0229028. PubMed ID: 32050011
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand.
Phisalprapa P; Supakankunti S; Chaiyakunapruk N
J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247
[No Abstract] [Full Text] [Related]
7. Cost Effectiveness of Hematopoietic Stem Cell Transplantation Compared with Transfusion Chelation for Treatment of Thalassemia Major.
John MJ; Jyani G; Jindal A; Mashon RS; Mathew A; Kakkar S; Bahuguna P; Prinja S
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2119-2126. PubMed ID: 29673692
[TBL] [Abstract][Full Text] [Related]
8. Cost-Utility and Cost-Effectiveness Analysis of Spinal Cord Stimulation for Chronic Refractory Pain in the Context of Developing Country.
Zinboonyahgoon N; Saengsomsuan N; Chaikittiporn N; Wangnamthip S; Kositamongkol C; Phisalprapa P
Pain Physician; 2023 Jan; 26(1):69-79. PubMed ID: 36791296
[TBL] [Abstract][Full Text] [Related]
9. Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.
Sun D; Heimall JR; Greenhawt MJ; Bunin NJ; Shaker MS; Romberg N
JAMA Pediatr; 2022 Feb; 176(2):176-184. PubMed ID: 34779842
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of an alcohol policy in Thailand: a case study of a random breath testing intervention.
Vichitkunakorn P; Khampang R; Leelahavarong P; Nontarak J; Assanangkornchai S
BMC Health Serv Res; 2024 Jun; 24(1):739. PubMed ID: 38886718
[TBL] [Abstract][Full Text] [Related]
11. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
[TBL] [Abstract][Full Text] [Related]
12. Cost-Utility of Video-Electroencephalography Monitoring Followed by Surgery in Adults with Drug-Resistant Focal Epilepsy in Thailand.
Kitwitee P; Unnwongse K; Srikijvilaikul T; Yadee T; Limwattananon C
World Neurosurg; 2017 Feb; 98():750-760.e3. PubMed ID: 27913266
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of national smoking cessation services among chronic obstructive pulmonary disease patients in Thailand.
Prasitwarachot R; Thavorn K; Patikorn C; Wattanasirichaigoon S; Rungruanghiranya S; Thongphiew A; Chaiyakunapruk N
J Med Econ; 2023; 26(1):1377-1385. PubMed ID: 37818930
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand.
Thongsri W; Bussabawalai T; Leelahavarong P; Wanitkun S; Durongpisitkul K; Chaikledkaew U; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):525-36. PubMed ID: 26566873
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of endovascular treatment for acute ischaemic stroke in Thailand.
Rattanavipapong W; Worakijthamrongchai T; Soboon B; Luankongsomchit V; Kongmuangpuk M; Isaranuwatchai W; Teerawattananon Y; Nilanont Y
BMJ Open; 2022 Sep; 12(9):e064403. PubMed ID: 36167373
[TBL] [Abstract][Full Text] [Related]
17. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
Permsuwan U; Thongprasert S; Sirichanchuen B
Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
[TBL] [Abstract][Full Text] [Related]
18. Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.
Kittiratchakool N; Kulpokin D; Chanjam C; Vilaiyuk S; Charuvanij S; Phongsamart G; Khaosut P; Tanya M; Nanagara R; Nantapaisarn S; Leelahavarong P
BMJ Open; 2020 Sep; 10(9):e037588. PubMed ID: 32933962
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
Sriphoosanaphan S; Pantumongkol W; Kulpeng W; Charonpongsuntorn C; Tanwandee T; Sukeepaisarnjaroen W; Sobhonslidsuk A; Tangkijvanich P
PLoS One; 2024; 19(3):e0300327. PubMed ID: 38512900
[TBL] [Abstract][Full Text] [Related]
20. Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.
Bamrungsawad N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P; Dechanont S; Wu DB; Dejthevaporn C; Chaiyakunapruk N
Clin Drug Investig; 2016 Jul; 36(7):557-66. PubMed ID: 27113227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
